{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T21:09:33Z","timestamp":1768770573958,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["19181MFDS402"],"award-info":[{"award-number":["19181MFDS402"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.neuropharm.2021.108917","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T20:24:33Z","timestamp":1638995073000},"page":"108917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The abuse potential of prolintane in rodents: Behavioral pharmacology approaches"],"prefix":"10.1016","volume":"205","author":[{"given":"Wonjong","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4337-4291","authenticated-orcid":false,"given":"Jung Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Mook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3284-6775","authenticated-orcid":false,"given":"Young-ki","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi-Seon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Ok","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1488-4110","authenticated-orcid":false,"given":"Mi Sun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.neuropharm.2021.108917_bib1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00213-006-0322-6","article-title":"3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings","volume":"189","author":"Baumann","year":"2007","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2021.108917_bib2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cobeha.2018.06.016","article-title":"Inclusion of females does not increase variability in rodent research studies","volume":"23","author":"Beery","year":"2018","journal-title":"Current opinion in behavioral sciences"},{"issue":"8","key":"10.1016\/j.neuropharm.2021.108917_bib3","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1046\/j.1460-9568.2003.02941.x","article-title":"Selective psychostimulant sensitization by food restriction: differential changes in accumbens shell and core dopamine","volume":"18","author":"Cadoni","year":"2003","journal-title":"Eur. J. Neurosci."},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108917_bib4","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00213-017-4526-8","article-title":"Behavioral evidence for the abuse potential of the novel synthetic cathinone alpha-pyrrolidinopentiothiophenone (PVT) in rodents","volume":"234","author":"Cheong","year":"2017","journal-title":"Psychopharmacology (Berlin)"},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108917_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0014-2999(82)90457-5","article-title":"Spontaneous climbing behaviour of mice, its measurement and dopaminergic involvement","volume":"85","author":"Costall","year":"1982","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108917_bib6","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00213-018-5059-5","article-title":"Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters","volume":"236","author":"Eshleman","year":"2019","journal-title":"Psychopharmacology (Berlin)"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108917_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/jpet.116.236349","article-title":"Structure-activity relationships of substituted cathinones, with transporter binding, uptake, and release","volume":"360","author":"Eshleman","year":"2017","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108917_bib8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/0091-3057(79)90233-8","article-title":"Effects of prolintane on 3,4-dihydroxyphenylacetic acid concentration in rat brain after spiperone treatment","volume":"10","author":"Fuller","year":"1979","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2021.108917_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1179\/acb.2002.076","article-title":"Nouvelles drogues de \u00ab rave-parties \u00bb : ketamine et prolintane","volume":"57","author":"Gaulier","year":"2002","journal-title":"Acta Clin. Belg."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108917_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/009127007001000205","article-title":"A new stimulant, prolintane hydrochloride, compared with dextroamphetamine in fatigued volunteers","volume":"10","author":"Hollister","year":"1970","journal-title":"J. Clin. Pharmacol. J. N. Drugs"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108917_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2131\/jts.39.1","article-title":"New recreational drug 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (alpha-PVP) activates central nervous system via dopaminergic neuron","volume":"39","author":"Kaizaki","year":"2014","journal-title":"J. Toxicol. Sci."},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108917_bib12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0893-133X(97)00195-4","article-title":"MDMA elicits behavioral and neurochemical sensitization in rats","volume":"18","author":"Kalivas","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108917_bib13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pbb.2015.07.013","article-title":"Sex differences in 3,4-methylenedioxypyrovalerone (MDPV)-induced taste avoidance and place preferences","volume":"137","author":"King","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"10","key":"10.1016\/j.neuropharm.2021.108917_bib14","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1021\/acschemneuro.5b00160","article-title":"Structural modification of the designer stimulant \u03b1-Pyrrolidinovalerophenone (\u03b1-PVP) influences potency at dopamine transporters","volume":"6","author":"Kolanos","year":"2015","journal-title":"ACS Chem. Neurosci."},{"issue":"12","key":"10.1016\/j.neuropharm.2021.108917_bib15","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1021\/cn4001236","article-title":"\"Deconstruction\" of the abused synthetic cathinone methylenedioxypyrovalerone (MDPV) and an examination of effects at the human dopamine transporter","volume":"4","author":"Kolanos","year":"2013","journal-title":"ACS Chem. Neurosci."},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108917_bib16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/jat\/31.7.415","article-title":"Domestic abuse of the European rave drug prolintane","volume":"31","author":"Kyle","year":"2007","journal-title":"J. Anal. Toxicol."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108917_bib17","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/106002809703100228","article-title":"Prolintane: a \"masked\" amphetamine","volume":"31","author":"Mart\u00ednez-Mir","year":"1997","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.neuropharm.2021.108917_bib18","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.neuropharm.2014.02.016","article-title":"Pharmacology of novel synthetic stimulants structurally related to the \"bath salts\" constituent 3,4-methylenedioxypyrovalerone (MDPV)","volume":"87","author":"Marusich","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108917_bib19","series-title":"Drug Addiction","author":"Mead","year":"2017"},{"key":"10.1016\/j.neuropharm.2021.108917_bib20","series-title":"Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants","author":"Moody","year":"2013"},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108917_bib21","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.neuroscience.2004.06.017","article-title":"Implications of protein kinase C in the nucleus accumbens in the development of sensitization to methamphetamine in rats","volume":"127","author":"Narita","year":"2004","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108917_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108917_bib23","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2125.1980.tb01790.x","article-title":"Wakefullness and reduced rapid eye movement sleep: studies with prolintane and pemoline","volume":"10","author":"Nicholson","year":"1980","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108917_bib24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1055\/s-2002-19829","article-title":"Visual hallucinations induced by the combination of prolintane and diphenhydramine","volume":"35","author":"Pay\u00e1","year":"2002","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108917_bib25","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0165-0173(97)00021-0","article-title":"A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants","volume":"25","author":"Pierce","year":"1997","journal-title":"Brain Res. Brain Res. Rev."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108917_bib26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF00506188","article-title":"Rat climbing behavior elicited by stimulation of cerebral dopamine receptors","volume":"325","author":"Protais","year":"1984","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108917_bib27","series-title":"Prolintane","author":"PsychonautWiki","year":"2020"},{"key":"10.1016\/j.neuropharm.2021.108917_bib28","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/0013-4694(64)90086-0","article-title":"The effect OF amphetamine ON the sleep cycle","volume":"16","author":"Rechtschaffen","year":"1964","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108917_bib29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41593-021-00806-8","article-title":"Considering sex as a biological variable will require a global shift in science culture","volume":"24","author":"Shansky","year":"2021","journal-title":"Nat. Neurosci."},{"issue":"20","key":"10.1016\/j.neuropharm.2021.108917_bib30","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1007\/s00213-015-4040-9","article-title":"Oral operant ethanol self-administration in the absence of explicit cues, food restriction, water restriction and ethanol fading in C57BL\/6J mice","volume":"232","author":"Stafford","year":"2015","journal-title":"Psychopharmacology (Berlin)"},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108917_bib31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.mp.4001507","article-title":"Dopamine in drug abuse and addiction: results from imaging studies and treatment implications","volume":"9","author":"Volkow","year":"2004","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2021.108917_bib32","series-title":"S6. Stimulants 2021 Prohibited List","first-page":"14","author":"WADA","year":"2021"},{"issue":"9","key":"10.1016\/j.neuropharm.2021.108917_bib33","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3109\/00498257409052094","article-title":"Metabolism of prolintane in rats and the effect of prolintane metabolites on general activities in mice","volume":"4","author":"Yoshihara","year":"1974","journal-title":"Xenobiotica"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821004743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821004743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:18:39Z","timestamp":1758439119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390821004743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":33,"alternative-id":["S0028390821004743"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108917","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The abuse potential of prolintane in rodents: Behavioral pharmacology approaches","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108917","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108917"}}